Drug‐induced immune‐mediated thrombocytopenia secondary to durvalumab use. Issue 6 (22nd June 2021)

• Record Type: Journal Article
• Authors: Dougherty, Sean C.; Lynch, Alia C.; Hall, Richard D.
• Is Part Of: Clinical case reports. Volume 9:Issue 6(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-06-22
• Subjects: ITP -- medical oncology -- pharmacokinetics -- platelets—acquired platelet disorders -- thrombocytopenia; Medicine -- Periodicals; 616.09
• DOI: 10.1002/ccr3.4227
• Languages: English
• ISSNs: 2050-0904

Abstract

Abstract: Immunotherapy is an expanding area of cancer treatment with significant promise. Despite their efficacy, checkpoint inhibitors are associated with a number of immune‐related adverse events; here, we described thrombocytopenia secondary todurvalumab. Abstract : Immunotherapy is an expanding area of cancer treatment with significant promise. Despite their efficacy, checkpoint inhibitors are associated with a number of immune‐related adverse events; here, we described thrombocytopenia secondary todurvalumab.